Long-acting injectable antipsychotics and the management of nonadherence

Psychiatric Annals

Volumn 41, Issue 5, 2011, Pages 271-278

  Weiden, Peter J ^a   Solari, Hugo ^a   Kim, Shiyum ^a   Bishop, Jeffrey R ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79960808458     PISSN: 00485713     EISSN: None     Source Type: Journal    
DOI: 10.3928/00485713-20110425-06     Document Type: Review

References (32)

1. Buchanan RW, Kreyenbuhl J, Kelly DL, et al; Schizophrenia Patient Outcomes Research Team (PORT). The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull. 201;36(1):71-93.
2. Velligan DI, Weiden PJ, Sajatovic M, et al. The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. J Clin Psychiatry. 2009;70(Suppl 4):1-46.
3. Miller AL, Hall CS, Buchanan RW, et al. The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2003 update. J Clin Psychiatry. 2004;65(4):500-508.
4. Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;71(Suppl 2):20-26.
5. Riley W, Velligan D, Sajatovic M, et al. Adherence to psychiatric treatments. Curr Med Lit Psychiatry. 2009;20(4):89-96.
6. Velligan DI, Lam YW, Glahn DC, et al. Defi ning and assessing adherence to oral antipsychotics: a review of the literature. Schizophr Bull. 2006;32(4):724-742.
7. Johnson DA. Historical perspective on antipsychotic long-acting injections. Br J Psychiatry Suppl. 2009;52:S7-S12.
8. Leucht C, Heres S, Kane JM, Kissling W, Davis JM, Leucht S. Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophrenia Res. 2011;127(1-3):83-92.
9. Hogarty GE, Schooler NR, Ulrich R, Mussare F, Ferro P, Herron E. Fluphenazine and social therapy in the aftercare of schizophrenic patients. Relapse analysis of a two-year controlled study of fl uphenazine decanoate and fl uphenazine hydrochloride. Arch Gen Psychiatry. 1979;36(12):1283-1294.
10. Johnson DA. Further observations on the duration of depot neuroleptic maintenance therapy in schizophrenia. Br J Psychiatry. 1979;135:524-530.
11. Denker SJ. The risk/benefi t ratio of depot neuroleptics: a Scandinavian perspective. J Clin Psychiatry. 1984;45(5 Pt 2):22-27.
12. Tiihonen J, Walhbeck K, Lonnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after fi rst hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
13. Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. A nationwide cohort study of oral and depot antipsychotics after fi rst hospitalization for schizophrenia. Am J Psychiatry. March 1, 2011 (epub ahead of print).
14. Blum A. Patients at risk of developing severe side effects from depot fl uphenazine treatment. Am J Psychiatry. 1980;137(2):254-255.
15. Ereshefsky L, Toney G, Saklad SR, Anderson C, Seidel D. A loading-dose strategy for converting from oral to depot haloperidol. Hosp Community Psychiatry. 1993;44(12):1155-1161.
16. Soni SD, Wiles D, Schiff AA, Bamrah JS. Plasma levels of fl uphenazine decanoate: Effects of site of injection, massage, and muscle activity. Br J Psychiatry. 1988;153:382-384.
17. Curson DA, Barnes TR, Bamber RW, Platt SD, Hirsch SR, Duffy JC. Long-term depot maintenance of chronic schizophrenic outpatients: the 7 year follow-up of the Medical Research Council fl uphenazine placebo trial. III Relapse postponement or relapse prevention? The implications for long-term outcome. Br J Psychiatry. 1985;146:474-480.
18. Babiker IE. Comparative effi cacy of long-acting depot and oral neuroleptic medications in preventing schizophrenic recidivism. J Clin Psychiatry. 1987;48(3):94-97.
19. Marder SR, Van Putten T, Mintz J, Lebell M, McKenzie J, May PR. Low- and conventional- dose maintenance therapy with fl uphenazine decanoate. Arch Gen Psychiatry. 1987;44(11):518-521.
20. Hogarty GE, McEvoy JP, Munetz M, et al. Dose of fl uphenazine, familial expressed emotion, and outcome in schizophrenia. Results of a two-year controlled study. Arch Gen Psychiatry. 1988;45(9):797-805.
21. Rosenheck RA, Krystal JH, Lew R, et al. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 2011;364(9):842-851.
22. Kane JM, Detke HC, Naber D, et al. Olanzapine long-acting injection: a 24-week, randomized, double-blind trial of maintenance treatment in patients with schizophrenia. Am J Psychiatry. 2010;167(2):181-189.
23. Levine J, Severe JB, et al. Prevention of relapse in schizophrenia: An evaluation of fl uphenazine decanoate. Arch Gen Psychiatry. 1980;37(1):16-24.
24. How generalizable are the results of clinical trials? Psychopharmacol Bull. 1980;16(3):29-31.
25. Weiden PJ, Schooler NR, Weedon JC, Elmouchtari A, Sunakawa A, Goldfi nger SM. A randomized controlled trial of long-acting injectable risperidone vs continuation on oral atypical antipsychotics for fi rst-episode schizophrenia patients: initial adherence outcome. J Clin Psychiatry. 2009;70(10):1397-1406.
26. Valenstein M, Copeland LA, Owen R, Blow FC, Visnic S. Adherence assessments and the use of depot antipsychotics in patients with schizophrenia. J Clin Psychiatry. 2001;62(7):545-551.
27. Masnik R, Bucci L, Isenberg D, Normand W. "Coffee and." A way to treat the untreatable. Am J Psychiatry. 1971;128(2):164-167.
28. Raskind P, Alvirez C, Herlin S. Fluphenazine enanthate with outpatient treatment of late paraphrenia. J Am Geriatr Soc. 1979;27(10):459-463.
29. Hogarty GE, Anderson C, Reiss D, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia II. Two-year effects of a controlled study on relapse and adjustment. Arch Gen Psychiatry. 1991;48(4):340-347.
30. Shear M, Frances A, Weiden PJ. Suicide associated with akathisia and depot fluphenazine treatment. J Clin Psychopharmacol. 1983;3(4):235-236.
31. Velligan DI, Lam F, Ereshefsky L, Miller AL. Psychopharmacology: perspectives on medication adherence and atypical antipsychotic medications. Psychiatr Serv. 2003;54(5):665-667.
32. Weiden P. Understanding and addressing adherence issues in schizophrenia: from theory to practice. J Clin Psychiatry. 2007;68(Suppl 14):14-19.